Standard BioTools Inc. - Common Stock (LAB)
0.9846
+0.0246 (2.56%)
NASDAQ · Last Trade: Mar 22nd, 7:25 AM EDT
Detailed Quote
| Previous Close | 0.9600 |
|---|---|
| Open | 0.9539 |
| Bid | 0.9503 |
| Ask | 1.010 |
| Day's Range | 0.9500 - 1.005 |
| 52 Week Range | 0.9200 - 1.720 |
| Volume | 3,784,425 |
| Market Cap | 373.03M |
| PE Ratio (TTM) | -2.984 |
| EPS (TTM) | -0.3 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 2,689,668 |
Chart
About Standard BioTools Inc. - Common Stock (LAB)
Standard BioTools Inc. is a biotechnology company that specializes in the development and commercialization of innovative tools and technologies for life sciences research and diagnostics. The company focuses on providing advanced solutions to enable researchers to better understand complex biological systems and streamline workflows in areas such as genomics, proteomics, and cell biology. By leveraging cutting-edge technologies and collaborative relationships with scientific communities, Standard BioTools aims to enhance the efficiency and accuracy of biological analysis, ultimately contributing to breakthroughs in healthcare and therapeutic development. Read More
News & Press Releases

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Via The Motley Fool · February 27, 2026

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Via The Motley Fool · February 27, 2026
Standard BioTools Inc (NASDAQ:LAB) Surges on Strong Q4 Earnings Beatchartmill.com
Via Chartmill · February 24, 2026
Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and Standard BioTools Inc. (NASDAQ: LAB) today announced a strategic collaboration to develop next-generation Imaging Mass Cytometry™ (IMC™) workflows powered by HCR imaging technologies, including the HCR HiFi Encoder for protein imaging with any primary antibody.
By Molecular Instruments · Via Business Wire · November 19, 2025

Standard BioTools just reported results for the second quarter of 2024.
Via InvestorPlace · July 31, 2024
Via Benzinga · November 18, 2025
Via Benzinga · June 25, 2025
This week, several emerging stocks are capturing investor attention with headline-making developments across defense tech, mining, HR, crypto gaming, wellness, and AI-driven diagnostics.
Via AB Newswire · June 23, 2025

Standard BioTools just reported results for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in multiomics.
Via Benzinga · June 23, 2025
Via Benzinga · June 23, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via Chartmill · June 23, 2025

Via Benzinga · January 13, 2025

Via Benzinga · August 27, 2024

Via Benzinga · August 19, 2024

Via Benzinga · August 12, 2024

Via Benzinga · August 2, 2024

Via Benzinga · August 1, 2024

Via Benzinga · August 1, 2024


